0000000000986360

AUTHOR

Saverio Ciriminna

showing 2 related works from this author

Prevalence of Genital Human Papilloma Virus Infection and Genotypes among Young Women in Sicily, South Italy

2008

Abstract Infection with oncogenic human papilloma virus (HPV) types is a necessary cause of cervical cancer. This study assessed the prevalence of HPV infection and genotypes among 1,006 randomly selected women, ages 18 to 24 years, living in Sicily (south Italy). The overall HPV rate was 24.1% (95% confidence interval, 21.5-26.9). The most frequent types were HPV-16 (4.5%), HPV-53 (2.7%), and HPV-84 (2.6%). The prevalence of vaccine types HPV-6, HPV-11, and HPV-18 was 1.4%, 0.1%, and 1.3%, respectively. Cytologic abnormalities were uncommon (3.1%) and associated with HPV detection (P < 0.0001). The only risk factor for HPV infection was the number of sexual partners (women with 2-3 …

medicine.medical_specialtyAdolescentGenotypeEpidemiologyYoung AdultEpidemiologymedicinePrevalenceHumansSex organYoung adultPapillomaviridaeRisk factorfemale genotype Human papillomavirusPapillomaviridaeCervical cancerChi-Square Distributionbiologybusiness.industryObstetricsPapillomavirus InfectionsHPV infectionvirus diseasesOdds ratioSexually Transmitted Diseases Viralbiology.organism_classificationmedicine.diseasefemale genital diseases and pregnancy complicationsLogistic ModelsOncologyItalyImmunologyFemalebusiness
researchProduct

Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients.

2008

OBJECTIVE: This is a multicentre, open label, prospective non-randomized registry, with 9-month angiographic follow-up, conducted to evaluate the safety and effectiveness of drug-eluting stents (DES) when used in high restenosis risk patients from the real world. METHODS: From June 2004 to February 2005, a total of 1622 consecutive patients were enrolled to the Sicilian DES Registry, according to specific inclusion criteria. Both paclitaxel-eluting and sirolimus-eluting stents were used. The analysis was performed on 1472 patients because 150 patients were excluded from the study. The primary endpoint was to evaluate the rate of major adverse cardiac events (MACE) within 9 months after DES …

Malemedicine.medical_specialtyPaclitaxelCoronary angioplastyRegistry.Target vessel revascularizationCoronary DiseaseCoronary AngiographyCoronary artery diseaseCoronary RestenosisRestenosisClinical endpointMedicineHumansCumulative incidencecardiovascular diseasesMyocardial infarctionDrug eluting stentRegistriesAngioplasty Balloon CoronarySicilyAgedSirolimusEjection fractionbusiness.industryIncidence (epidemiology)Drug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryFemaleCardiology and Cardiovascular MedicinebusinessMaceDiabetic AngiopathiesImmunosuppressive AgentsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct